Indian Drugs and Pharmaceuticals
Corporate brand
UnclaimedIndian government-owned pharmaceutical company associated with essential medicines, bulk drugs, drug discovery, and public-sector pharmaceutical manufacturing.
Last updated August 26, 2026
Overview
Indian Drugs and Pharmaceuticals Limited (IDPL) was an Indian government-owned pharmaceutical company established in 1961. It operated as a public-sector manufacturer of pharmaceuticals and bulk drugs and was also associated with drug-discovery and patent-development work. The company’s stated public-sector role placed emphasis on the production of affordable and essential medicines rather than on the positioning of a consumer-facing commercial brand. IDPL was headquartered in New Delhi and maintained operating locations in Hyderabad, Gurgaon, and Rishikesh. Its activities covered pharmaceutical manufacturing and the production of active or bulk drug ingredients. The company also worked with the National Institute of Pharmaceutical Education and Research, Hyderabad, in areas connected with patent development and the pursuit of affordable medicines. This relationship reflected a broader public-interest objective: strengthening domestic pharmaceutical capabilities and supporting access to lower-cost products. The company’s later history was dominated by financial and operational difficulty. IDPL was declared sick by the Board for Industrial and Financial Reconstruction, after which successive efforts were considered to revive the enterprise. The Government of India explored strategic-sale options as a way to address the company’s liabilities and determine a future for its facilities. These efforts did not restore the business to a sustainable operating position. A formulation unit was inaugurated in Hyderabad in February 2017, indicating that the government and associated stakeholders still pursued some form of production or capability renewal at that stage. The company also released three over-the-counter medicines in the period described by the available reference material. These developments coexisted with the larger structural problems affecting IDPL and did not prevent the eventual decision to wind up the company. On 9 February 2021, the Government of India announced the liquidation of IDPL. The announcement marked the end of the company as an operating public-sector pharmaceutical enterprise. Because the available reference material provides limited detail on the individual medicines, financial results, executives, ownership structure beyond government control, and the precise status of each production site, those fields are left unexpanded here.
History
Indian Drugs and Pharmaceuticals Limited was established in 1961 as a government-owned pharmaceutical enterprise in India. Its creation formed part of the country’s effort to build domestic capacity in medicines and pharmaceutical inputs. IDPL’s remit extended beyond the sale of finished medicines: it was associated with bulk-drug manufacturing, pharmaceutical formulations, and drug-discovery or patent-development activities intended to support affordable access to medicines. The company was headquartered in New Delhi and had locations in Hyderabad, Gurgaon, and Rishikesh. Hyderabad was particularly relevant to its later manufacturing and research profile. IDPL also worked alongside the National Institute of Pharmaceutical Education and Research, Hyderabad, in patent-development activity and the pursuit of affordable drugs. The available reference material describes the company as having released three over-the-counter medicines, although it does not identify their names or provide launch dates. IDPL’s public-sector role was accompanied by persistent financial and operational challenges. The company was declared sick by the Board for Industrial and Financial Reconstruction. There were multiple attempts to revive it, and the Government of India examined a strategic sale as one possible route for restructuring the enterprise and meeting outstanding liabilities. The available sources do not provide a complete chronology of these attempts, details of bidders, or the final liability figures. A new formulation unit was inaugurated in Hyderabad in February 2017. The project represented a later effort to maintain or renew manufacturing capability, but it did not resolve the broader difficulties surrounding the company. By this point, IDPL’s history combined an original developmental mandate with the problems faced by a financially distressed public-sector manufacturer. On 9 February 2021, the Government of India announced the liquidation of IDPL. This decision ended the company’s existence as an operating government-owned pharmaceutical business and superseded the earlier revival and strategic-sale discussions. The reference material does not establish whether individual facilities, patents, products, or employees were transferred to another organization. Consequently, the company is recorded as defunct, with its historical significance resting primarily on its role in India’s public pharmaceutical sector and its contribution to domestic manufacturing capacity.
- 2021
Liquidation announced
[1]The Government of India announced the liquidation of IDPL on 9 February 2021.
- 2017
Hyderabad formulation unit inaugurated
[1]A new formulation unit was inaugurated in Hyderabad in February, reflecting an effort to sustain or expand manufacturing capability.
- 1961
Company established
[1]Indian Drugs and Pharmaceuticals was established as a government-owned Indian pharmaceutical company.
Products and positioning
Indian public-sector pharmaceutical manufacturer focused on essential medicines, bulk drugs, affordable pharmaceuticals, and domestic drug-development capability.
Pharmaceuticals
Essential medicines
Essential medicines formed part of IDPL’s public-sector pharmaceutical role. The company was associated with producing medicines intended to support domestic availability and affordability, although the available reference material does not provide a complete product catalogue or identify specific active ingredients and formulations.
Pharmaceutical ingredients
Bulk drugs and active pharmaceutical ingredients
IDPL was involved in bulk-drug manufacturing, meaning pharmaceutical substances and inputs used in the preparation of finished medicines. This activity supported the company’s role in domestic supply and industrial pharmaceutical capacity. The sources do not specify the individual ingredients manufactured or their production volumes.
Finished medicines · 2017
Pharmaceutical formulations
The company produced pharmaceutical formulations and inaugurated a new formulation unit in Hyderabad in February 2017. The available material does not identify the unit’s therapeutic focus, capacity, or full product range, but the facility represented a continuation of IDPL’s finished-medicine manufacturing activities.
Consumer healthcare
Over-the-counter medicines
IDPL had released three over-the-counter medicines according to the available reference material. Their names, formulations, launch dates, and distribution footprint are not identified in the cited source, so they cannot be listed individually.
Brand decisions
2021
Liquidation of IDPLStrategyBackground
IDPL had been declared sick by the Board for Industrial and Financial Reconstruction, and revival and strategic-sale options had been considered in response to its liabilities and financial distress.
Action taken
The Government of India announced the liquidation of Indian Drugs and Pharmaceuticals on 9 February 2021.
Aftermath
The announcement marked the end of IDPL as an operating government-owned pharmaceutical enterprise. The source does not specify the disposition of its facilities, products, patents, or workforce.
2017
Inauguration of Hyderabad formulation unitProduct launchBackground
IDPL faced longer-term financial and operational difficulties but continued to pursue pharmaceutical manufacturing capability.
Action taken
A new formulation unit was inaugurated in Hyderabad in February 2017.
Aftermath
The unit’s inauguration did not prevent the later decision to liquidate the company. The available source does not describe its subsequent operating status.
Recent events
- 2021
Government of India announced liquidation of IDPL[1]
Bankruptcy
On 9 February 2021, the Government of India announced that Indian Drugs and Pharmaceuticals would be liquidated.
- 2017
Hyderabad formulation unit inaugurated[1]
Product launch · Other
A new formulation unit associated with Indian Drugs and Pharmaceuticals was inaugurated in Hyderabad in February 2017.
Government explored strategic sale amid revival efforts[1]
Other
After IDPL was declared sick by the Board for Industrial and Financial Reconstruction, the Government of India considered revival measures and explored a strategic sale to address outstanding liabilities.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/indian-drugs-and-pharmaceuticals · Editorial policy · How profiles are compiled